This editorial refers to 'Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK' † , by Regardless of the definition, FH can be reliably diagnosed and therefore meets the criteria for screening. Statins, with or without ezetimibe, are effective both in terms of LDL-cholesterol and CVD risk lowering. In a recent study, statins were shown to reduce the CVD risk by almost 50% among FH patients.
Almost five decades ago, Wilson and Jungner formulated 10 criteria to guide the selection of conditions for universal screening, which have essentially become the policy standard to date. 1 In particular, conditions
should pose an important health problem for which reliable and effective tests and therapies are available, and the overall costs of screening should be acceptable. Judged by these criteria, familial hypercholesterolaemia (FH) is an obvious condition for population screening.
FH screening: why?
Recent advances in DNA sequencing technologies have enabled large-scale genetic analyses in population studies. Based on these studies, we now know that FH is much more common than previously anticipated. [2] [3] [4] [5] While it is now widely recognized that 1 out of 200-250 individuals has FH, the majority of FH patients remain undiagnosed and untreated. Recent studies confirmed a three-to fourfold increased risk of (premature) cardiovascular disease (CVD), with an even higher risk among individuals with particularly deleterious mutations. [2] [3] [4] [5] Much remains to be achieved to reduce the burden of CVD among FH patients, as emphasized by a recent Norwegian study in which the mean age of death among FH patients was 60 years, at which point 93% had CVD. 6 The argument that FH poses an 'important health problem' can therefore be easily made. The definition of FH remains a topic of debate, with implications for diagnosis and screening. Diagnostic algorithms [e.g. Dutch Lipid Clinic Network (DLCN) and Simon Broome criteria] are commonly used to calculate the likelihood of monogenic FH based on clinical characteristics. Nevertheless, mutations cannot be identified in a substantial proportion of patients with phenotypic FH. 2 Khera et al. recently showed in a large cohort that <2% of individuals with LDLcholesterol >190 mg/dL had FH mutations. 4 Conversely, 27% of LDL receptor mutation carriers had LDL-cholesterol <130 mg/dL. 4 Regardless of the definition, FH can be reliably diagnosed and therefore meets the criteria for screening. Statins, with or without ezetimibe, are effective both in terms of LDL-cholesterol and CVD risk lowering. In a recent study, statins were shown to reduce the CVD risk by almost 50% among FH patients. 7 All statins and ezetimibe will be generic compounds in 2018, making these drugs very affordable and widely available. Nevertheless, a large proportion of FH patients fail to achieve guideline-recommended LDLcholesterol goals, and the residual burden of CVD remains substantial. 4, 8 Fortunately, novel therapies such as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors have been shown to be highly effective in these patients, essentially curing the consequences of the genetic defect if started early enough. 9 Thus, FH is a highly prevalent and underdiagnosed disease which can now be efficiently detected and effectively treated, making it an ideal candidate for screening. Nevertheless, economic evaluation is required to guide policymakers in their decision about whether or not to subsidize large-scale FH screening. In this issue of the journal, Kerr et al. demonstrate the cost-effectiveness of FH cascade screening in the UK using real-life data, while taking into account the declining costs of diagnosis and treatment. 10 
FH screening: how?
There are several approaches to FH screening. The feasibility of national universal screening among children is shown in Slovenia, where serum cholesterol is measured at the age of 5 years. An FH mutation was found in more than half of children who were suspected to have FH based on the screening results. 11 Universal screening entails an all-encompassing approach and enables unmatched opportunities to identify FH patients. Furthermore, combining such screening with routine (immunization) visits would be expected to increase participation rates, and the focus on children enables early intervention. Another advantage of universal screening is that it provides an inroad into identifying index cases for cascade screening, such as the 'childparent screening' described by Wald et al. 12 The study by Wald et al.,
however, also highlighted some difficulties of universal cholesterol screening. Serum cholesterol was determined among >10 000 infants during immunization visits, followed by DNA testing. 12 As expected, the overlap between positive cholesterol screening and monogenic FH depended on the chosen cholesterol cut-off value. Variable genotype-phenotype associations, including incomplete penetrance, may undermine the reliability of cholesterol-based screening. In addition, universal screening requires major investments in terms of infrastructure and organization, whereas the long-term benefits are not well defined.
In contrast, the effectiveness of cascade screening is well documented. This approach is recommended by various professional societies and has been implemented at a national level in mostly European countries. The overall costs and benefits of cascade screening depend on the identification of index patients, as well as factors such as the prevalence of FH within the population, baseline risk, and treatment effects. Of note, new diagnostic models may increase the yield of genetic screening among suspected FH patients. 13 Uncertainties regarding these factors, combined with investments required to organize effective cascade screening programmes (although much lower than those required for universal screening), probably explain the reluctance to implement this screening more widely.
Is FH screening economically viable?
In 2013, Ademi et al. reviewed the literature to evaluate the costeffectiveness of screening for FH. 14 Overall, cascade screening appeared to be cost-effective, but the reliability of the analyses critically depended on estimates regarding population characteristics, treatment effects, costs, and screening accuracy. Some of the issues identified by Ademi et al. were addressed in the current evaluation, whose authors used real-life data to replace previous assumptions. Kerr et al. developed a Markov model to estimate the costeffectiveness of cascade screening for FH, compared with no screening or treatment. Data from the UK cascade services were used as input variables for index testing, monogenic FH diagnosis rate, relative testing, and LDL-cholesterol. Baseline CVD risks were estimated using relative risks from Simon Broome and general population risks. To estimate the effect of treatment among newly identified patients, the authors used data on LDL-cholesterol reductions from the 2010 UK FH audit and the observed risk reduction in a large meta-analysis of statin trials. Several sensitivity analyses were performed to provide a range of estimates. The authors conclude that cascade screening in FH families is highly cost-effective, with a cost per quality-adjusted life year (QALY) of £5806 per tested relative.
The study contributes to the existing literature which has quite consistently confirmed the cost-effectiveness of FH cascade screening across populations and settings. The conclusions are in line with recent evaluations from The Netherlands, Australia, and Spain, which similarly used real-life data. [15] [16] [17] Nevertheless, the number and extent of the assumptions in the analysis by Kerr and colleagues may have had a large effect on the estimates. Incorporation of data from several previous studies could have yielded more precise results.
To estimate the CVD risk of identified individuals, the authors used data from Simon Broome. Although this cohort is widely used and regarded as an appropriate way to estimate CVD risk of FH patients, it should be emphasized that this cohort comprises individuals referred to specialized lipid clinics with markedly elevated serum cholesterol and CVD risk. 18 The CVD risk might therefore have been inflated and this will result in an overestimated screening benefit. In the base case, the authors assume that identified FH patients did not use lipid-lowering drugs prior to the DNA diagnosis, which has a large effect on the CVD outcome. However, it is also noted that >40% actually did receive therapy prior to their diagnosis, which is in line with observations among newly identified FH patients in The Netherlands. 19 The inconsistency between the model and 'real life' again will have an impact on the net cost-benefit ratio of cascade screening. Furthermore, the main analysis does not take into account the observations that 9% of relatives with FH mutations are normocholesterolaemic. Treatment effects will depend on baseline LDL-cholesterol, and the model has not accounted for non-penetrance, which may have overestimated the treatment effect. 20 Moreover, the authors relied on UK audit data to estimate LDL-cholesterol reductions combined with data from statin trials conducted in heterogeneous populations, and large-scale trials have not been conducted in FH patients. We deem the estimated effect size relatively accurate, given the fact that we observed a similar effect in a recently performed analysis. 7 Sensitivity analyses were performed to account for the possible inaccuracy of some of the assumptions. These analyses showed that individually the assumptions did not have a large impact on the results of the evaluation. However, the impact of the combination of potentially inaccurate assumptions is not clear.
The model assumes that the treatment of index cases remains unchanged following DNA diagnosis. However, we have previously reported that genetic confirmation may prompt more aggressive lipid-lowering treatment, and the authors' assumption may have therefore led to an underestimation of the merits of genetic testing and cascade screening. 19 It is also worth noting that the number of relatives screened per index patient was low compared with other reports, as well as compared with the number reported in Northern Ireland. 16 The importance of the number of screened relatives is highlighted by the notion that the net costs of screening would decline by 54% if the ratio would be increased to the level observed in Northern Ireland, as shown in the sensitivity analysis. A major 'elephant in the room' relates to the costs and benefits of PCSK9 inhibitors, which have recently been introduced in clinical practice. The results of the FOURIER trial of evolocumab confirmed that PCSK9 inhibitors improve clinical outcomes. Many FH patients would be eligible to receive these drugs given the low rate of patients who achieve desired LDL-cholesterol levels with currently available therapies. Regardless of their clinical efficacy, the high costs of PCSK9 inhibitors imply that they will have a major impact on the costeffectiveness of FH screening programmes.
Conclusion and future directions
The consistent conclusions of analyses about the cost-effectiveness of FH cascade screening programmes should be perceived as a justification for their wider implementation. However, the validity and applicability of such analyses rely on local practice, the accuracy of assumptions, as well as on future developments in the cost for genetic testing and medical treatment ( Figure 1) . Notably, novel drugs may substantially improve clinical outcomes for FH patients, but their high costs may negatively impact the cost-effectiveness of screening initiatives. On the other hand, reduced costs of conventional therapies and more efficient and cheaper diagnostic tests make screening increasingly attractive from a societal perspective. Figure 1 The balance is currently in favour of wider implementation of FH cascade screening programmes.
